Koppikar Utpal has filed 4 insider transactions across 2 companies since February 2023.
Most recent transaction: a grant/award of 35500 shares of C4 Therapeutics, Inc. ($CCCC) on June 18, 2025.
Activity breakdown: 0 open-market purchases and 2 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| June 18, 2025 | C4 Therapeutics, Inc. | $CCCC | Koppikar Utpal | Director | A | Stock Option (Right to Buy) | 35500 | $0.00 | 35,500.0000 | 70,989,661 | 9999.99% | 0.05% |
| June 20, 2024 | C4 Therapeutics, Inc. | $CCCC | Koppikar Utpal | Director | A | Stock Option (Right to Buy) | 32500 | $0.00 | 32,500.0000 | 0 | 9999.99% | 0.00% |
| March 2, 2023 | Atara Biotherapeutics, Inc. | $ATRA | Koppikar Utpal | Chief Financial Officer | S | Common Stock | 6871 | $3.63 | 181,978.0000 | 0 | 3.64% | 0.00% |
| Feb. 7, 2023 | Atara Biotherapeutics, Inc. | $ATRA | Koppikar Utpal | Chief Financial Officer | S | Common Stock | 2485 | $5.46 | 188,849.0000 | 0 | 1.30% | 0.00% |